Unlock instant, AI-driven research and patent intelligence for your innovation.

Clostridium difficile polypeptides as vaccine

A technology of Clostridium difficile and polypeptide fragments, applied in the field of polypeptides of Clostridium difficile, can solve problems such as the inability to completely prevent colonization pathogens

Inactive Publication Date: 2015-04-29
NOVARTIS AG
View PDF31 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, toxin-based vaccines only prevent toxin binding, neutralizing inflammatory effects; such vaccines usually do not completely prevent colonization or clear the present pathogen from the body

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Clostridium difficile polypeptides as vaccine
  • Clostridium difficile polypeptides as vaccine
  • Clostridium difficile polypeptides as vaccine

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0240] Example 1: Identification of Clostridium difficile polypeptides

[0241] To identify polypeptides for use in vaccines against C. difficile, the inventors analyzed the repertoire of approximately 3780 predicted polypeptides encoded by C. difficile 630 using the PSORT program (220). The identified protein has a predicted peripheral subcellular localization. Specifically, the following groups were identified:

[0242] • Cell wall-associated proteins, identified by the presence or absence of a typical LPXTG-like motif representing the site that attaches the protein to the outside of the bacterial cell wall.

[0243] • Extracellular proteins, identified by the presence of an N-terminal leader peptide (which normally directs the protein product to the extracellular matrix) and / or by sequence similarity to other bacterial proteins known to be exported.

[0244] • Proteins with bacterial surface localization.

[0245] Other polypeptides are selected based on their sequence...

Embodiment 2

[0246] Example 2: Identification of secreted C. difficile polypeptides

[0247]C. difficile secretome preparations were performed as follows: C. difficile (strains 630 and Stoke Mandeville) were grown in brain heart infusion (BHI) or chemically defined medium (CDM, M.N. Mickelson, J. of Bact., 1964, 88:158-164). Bacteria were plated overnight on agar plates and subsequently grown anaerobically in 100 mL of the appropriate medium at 37 °C until mid-log phase (OD 600 0.5) or early stable period (OD 600 is 0.9). Bacteria were removed by centrifugation at 3,500 xg for 10 minutes at 4°C and the supernatant was filtered through a 0.22 μm pore size filter (Millipore). Proteins in the supernatant were precipitated overnight using 10% w / v trichloroacetic acid, 0.04% w / v sodium deoxycholate. Resuspend the protein in a solution containing 5mM dithiothreitol, 0.1% (Waters) in 50 mM ammonium bicarbonate, heated at 90° C. for 10 minutes and digested overnight with 2 ug of trypsin (P...

Embodiment 3

[0252] Example 3: Analysis of cell lysates by NMR

[0253] Bacterial cells carrying vectors for recombinant protein expression were initially washed by resuspending in 800 uL M9 1X buffer (pH 7.4), centrifuging (5 min at 3,000 rpm) and discarding the supernatant. The remaining bacterial pellet was resuspended in 600 uL of M9 buffer, and cells were lysed by sonication followed by centrifugation at 4°C (14,000 rpm, 20 minutes). The supernatant was then isolated for NMR analysis. 10% D2O (by volume) was added to the samples for NMR analysis. Use 900 or 800MHz NMR to acquire fast HSQC or TROSY experiments and process through topspin software ( image 3 ).

[0254] In NMR analysis, the HSQC spectrum of Dif44 shows a good dispersion of pictures (pics), where Figure 4 Roughly equal intensities in show that Dif44 is well folded. The results of NMR analysis of cell lysates are summarized in figure 2 . These results identify polypeptides with a propensity to stably maintain t...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Diameteraaaaaaaaaa
Login to View More

Abstract

The invention provides methods, proteins, nucleic acids and antibodies for preventing or treating a Clostridium difficile infection in a mammal.

Description

technical field [0001] The present invention relates to a polypeptide derived from Clostridium difficile (C.difficile), especially a method for using the polypeptide to treat and prevent Clostridium difficile infection. Background technique [0002] Clostridium difficile is a Gram-positive, rod-shaped, anaerobic spore-forming bacterium. The first fully sequenced C. difficile genome was published in 2006 [1] and identified 3776 predicted coding sequences. Clostridium difficile is a common component of the gut microbiota, comprising an estimated 3% of the total population in the absence of evidence of disease. C. difficile becomes more prevalent when the natural balance of gut flora is disturbed. This overgrowth causes the bacteria to start producing toxins under the control of quorum signaling regulators. The most common reason for disturbing the natural balance of gut flora is the administration of antibiotics that are harmful to some gut bacteria but not C. difficile. C...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K39/08A61K39/40C07K14/33C07K16/12C12N15/31A61P31/04
CPCA61K39/08C07K16/1282A61K2039/55505A61K2039/55566A61K2039/70C07K14/33A61P1/00A61P1/12A61P31/04A61P37/08
Inventor C·加莱奥蒂R·里犹兹M·皮萨M·斯卡塞利M·乌尼克里西南M·马丁内利
Owner NOVARTIS AG